within Pharmacolibrary.Drugs.ATC.S;

model S01EB09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.5,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EB09</td></tr><td>route:</td><td>intraocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Acetylcholine is an endogenous neurotransmitter and parasympathomimetic drug. It is mainly used in clinical practice as an ophthalmic agent to induce miosis during ocular surgery. Due to its rapid hydrolysis by cholinesterases, it is not used systemically. It is approved for intraocular use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for intraocular administration, since IV or oral use is not clinically relevant due to extreme rapid breakdown; pharmacokinetic parameters are not reported in the literature for humans.</p><h4>References</h4><ol><li><p>Booij, LH (1997). Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. <i>Pharmacy world &amp; science : PWS</i> 19(1) 13–34. DOI:<a href=\"https://doi.org/10.1023/a:1008641427473\">10.1023/a:1008641427473</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9089750/\">https://pubmed.ncbi.nlm.nih.gov/9089750</a></p></li><li><p>Mata, D, et al., &amp; Linn, CL (2015). Retinal ganglion cell neuroprotection induced by activation of alpha7 nicotinic acetylcholine receptors. <i>Neuropharmacology</i> 99 337–346. DOI:<a href=\"https://doi.org/10.1016/j.neuropharm.2015.07.036\">10.1016/j.neuropharm.2015.07.036</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26239818/\">https://pubmed.ncbi.nlm.nih.gov/26239818</a></p></li><li><p>Hui, M, et al., &amp; Lam, DS (2011). In vitro compatibility study of cephalosporin with intraocular irrigating solutions and intracameral medications. <i>Clinical &amp; experimental ophthalmology</i> 39(2) 164–170. DOI:<a href=\"https://doi.org/10.1111/j.1442-9071.2010.02402.x\">10.1111/j.1442-9071.2010.02402.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20796261/\">https://pubmed.ncbi.nlm.nih.gov/20796261</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EB09;
